K. **Review and Limitations for Opioid Claims.** The state will perform the following reviews and actions for claims related to opioids:

1. Prospective safety edits on opioid prescriptions for early duplicate, early refills, and fills in excess of clinically appropriate standards.
2. Prospective safety edits to limit maximum daily morphine milligram equivalents (MME) as recommended by clinical guidelines.
3. Ongoing, retrospective reviews on opioid prescriptions in excess of limits.
4. Ongoing, retrospective reviews for concurrent utilization of opioids and benzodiazepines, and concurrent utilization of opioids and antipsychotics.

L. **Programs to Monitor Antipsychotic Medications to Children.** The state will review prescriptions for antipsychotic agents for appropriateness for all children, including children in foster care, for clinic appropriateness.

M. **Fraud and Abuse Identification.** The DUR program includes a process that identifies potential fraud or abuse of controlled substances by enrollees and/or health care providers.

TN No. 19-18

Approval Date: ______

Effective Date: October 1, 2019

Supercedes: N/A